Spinal Muscular Atrophy is a genetic neuromuscular disorder caused by SMN1 mutations, leading to insufficient survival motor neuron protein and progressive motor-neuron loss and muscle atrophy.
Spinal Muscular Atrophy is a genetic neuromuscular disorder caused by SMN1 mutations, leading to insufficient survival motor neuron protein and progressive motor-neuron loss and muscle atrophy. Stem-cell research explores neurogenic cells to support or replace motor neurons and placental mesenchymal stem cells to secrete neuroprotective factors and reduce neuroinflammation. Because SMA is genetic, cellular approaches that do not correct the underlying SMN deficiency may offer limited long-term benefit. This distinguishes SMA from acquired disorders, and helps explain why approved gene-targeted therapies dominate care. Trials are very few; reported outcomes focus on motor-function stabilisation rather than recovery.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €15,000–€30,000 (bioinformant.com) |
| Main cell types studied | Neurogenic Cells, MSCs from Amniotic Membrane |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 5 · 1 recruiting now |
For the clinic's own description, see how Stem Plus describes its Spinal Muscular Atrophy programme ↗.
Five registered trials and 1 recruiting study address stem-cell therapy in SMA — the smallest landscape among the conditions here. Published data are sparse and largely single-centre observational. Some describe stabilisation or slowed decline over 6–12 months; others minimal change. SMA's rapid natural progression makes any stability potentially notable, but separating stem-cell effects from approved disease-modifying therapies (nusinersen, gene therapy) is difficult without controls. No trial has reversed motor-neuron loss.
Depending on assessment, a Spinal Muscular Atrophy protocol may draw on:
Indicative costs, where offered, are roughly €4,500–€7,500 per course — availability is limited given sparse evidence. For context, approved SMA disease-modifying therapies are extremely expensive but insurance-covered and proven, which sets a high bar: a stem-cell approach would need to match their benefit to justify out-of-pocket cost. The figure is indicative only.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Spinal Muscular Atrophy cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Spinal Muscular Atrophy.
Full Spinal Muscular Atrophy FAQ → · Spinal Muscular Atrophy cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка